文献速递儿童呼吸

地塞米松在儿童哮喘急性发作中的应用趋势与结局

Adoption of Dexamethasone for Asthma Exacerbations.
PubMed 文献 · Pediatrics · 2025-01-01

BACKGROUND: Previous work has demonstrated that dexamethasone has similar efficacy to prednisolone/prednisone for the management of asthma exacerbations.…

要点

  • 地塞米松与7天内再就诊风险略高相关(aOR 1.07,95%CI 1.03-1.11)。
  • 地塞米松与7天内住院风险更低相关(aOR 0.90,95%CI 0.84-0.97)。

核心结论

  • 儿童哮喘急诊离院后地塞米松使用呈显著增长趋势,2013至2015年间增长尤为明显。
  • 与泼尼松/泼尼松龙相比,地塞米松与7天内再就诊风险略高但住院风险更低相关。

研究设计与样本

  • 回顾性横断面分析,纳入2010至2024年28家医院中<18岁因哮喘急性发作从急诊离院并接受地塞米松或泼尼松/泼尼松龙的儿童。

主要发现

  • 地塞米松与7天内再就诊调整OR为1.07(95%CI 1.03-1.11),与7天内住院调整OR为0.90(95%CI 0.84-0.97)。

临床怎么用

  • 临床可考虑地塞米松作为儿童哮喘急性发作急诊离院后的皮质类固醇选择之一。
  • 选择地塞米松时需权衡再就诊风险略高与住院风险更低的结局差异。

局限性

  • 回顾性设计可能受混杂因素影响。
  • 仅纳入急诊离院儿童,结果不能外推至住院或其他场景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous work has demonstrated that dexamethasone has similar efficacy to prednisolone/prednisone for the management of asthma exacerbations. We sought to evaluate trends in the use of dexamethasone for asthma among children discharged from the emergency department (ED) and to evaluate the association of corticosteroid choice with return visits and hospitalizations. METHODS: We conducted a retrospective cross-sectional analysis of 28 hospitals between 2010 and 2024, including children (<18 years) discharged from the ED with an acute asthma exacerbation who received either dexamethasone or prednisolone/prednisone. We identified trends in corticosteroid selection using breakpoint analysis and evaluated the association of corticosteroid selection with any ED return visit and return visits leading to hospitalization within 7 days. RESULTS: We included 491 576 encounters (median age of 6.2 years [IQR 4.0-9.8]; 62.4% for boys). Of these, 216 874 (44.1%) received prednisolone/prednisone and 274 702 (55.9%) received dexamethasone. There was an increase in use of dexamethasone (91.1% given prednisolone/prednisone in 2010; 95.3% given dexamethasone by 2024). We identified breakpoints in September 2013 and December 2015. During the 27-month period between these points, adoption of dexamethasone increased by 0.7% per month, (95% CI 0.6-0.9%). Dexamethasone was associated with a higher adjusted odds of return visit (1.07, 95% CI 1.03-1.11) and a lower adjusted odds of hospitalization within 7 days relative to prednisolone/prednisone (0.90, 95% CI 0.84-0.97). CONCLUSION: We identified a transition toward dexamethasone use for children with asthma discharged from pediatric EDs. This was particularly pronounced between 2013 and 2015, approximately 15 years after the first dexamethasone trials were published.

来源:Pediatrics,查看原文。版权归原作者所有。

引用

  1. Ramgopal S, Michelson KA. Adoption of Dexamethasone for Asthma Exacerbations. Pediatrics. 2025. PMID: 40467067. doi:10.1542/peds.2024-070153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。